Dietary factors, genetic and epigenetic influences in colorectal cancer (Review)

Pellegrini,M. L.; Argibay,P.; Gomez,D. E.

doi:10.3892/etm_00000038

Dietary factors, genetic and epigenetic influences in colorectal cancer (Review)

Authors:
- M. L. Pellegrini
- P. Argibay
- D. E. Gomez
View Affiliations

Affiliations: Instituto de Ciencias Básicas y Medicina Experimental, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
Published online on: March 1, 2010 https://doi.org/10.3892/etm_00000038
Pages: 241-250

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Genetic influences, together with epigenetic components and dietary factors, play a fundamental role in the initiation and progression of cancer by causing a number of deregulations. Colorectal cancer (CRC) is a disease influenced by dietary factors, for which established genetic and epigenetic alterations have been identified. Within CRC, there are hereditary syndromes that present mutations in the germ-line hMLH1, and also alterations in the methylation of the promoters. Epigenetics has also been established as a pathway of carcinogenesis. In the present review, we analyzed studies conducted to discern the different pathways leading to established CRC, stressing the importance of identifying factors that may predict CRC at an early stage, since it is mostly a silent disease observed at the clinical level in advanced stages.

View Figures

View References

1.	Lynch HT and de la Chapelle A: Hereditary colorectal cancer. N Engl J Med. 348:919–932. 2003. View Article : Google Scholar : PubMed/NCBI
2.	Calvert PM and Frucht H: The genetics of colorectal cancer. Ann Intern Med. 137:603–612. 2002. View Article : Google Scholar : PubMed/NCBI
3.	Lynch HT, Lanspa S, Smyrk T, Boman B, Watson P and Lynch J: Hereditary nonpolyposis colorectal cancer (Lynch syndromes I & II). Genetics, pathology, natural history and cancer control, Part I. Cancer Genet Cytogenet. 53:143–160. 1991.
4.	Terdiman JP, Conrad PG and Sleisenger MH: Genetic testing in hereditary colorectal cancer: indications and procedures. Am J Gastroenterol. 94:2344–2356. 1999. View Article : Google Scholar
5.	Cheung P and Lau P: Epigenetic regulation by histone methylation and histone variants. Mol Endocrinol. 19:563–573. 2005. View Article : Google Scholar
6.	Hoffmann MJ and Schulz WA: Causes and consequences of DNA hypomethylation in human cancer. Biochem Cell Biol. 83:296–321. 2005. View Article : Google Scholar
7.	Herman JG and Baylin SB: Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 349:2042–2054. 2003. View Article : Google Scholar : PubMed/NCBI
8.	Holliday R: Epigenetics: a historical overview. Epigenetics. 1:76–80. 2006. View Article : Google Scholar
9.	Esteller M: Relevance of DNA methylation in the management of cancer. Lancet Oncol. 4:351–358. 2003. View Article : Google Scholar : PubMed/NCBI
10.	Robertson KD and Wolffe AP: DNA methylation in health and disease. Nat Rev Genet. 1:11–19. 2000. View Article : Google Scholar
11.	Warnecke PM and Bestor TH: Cytosine methylation and human cancer. Curr Opin Oncol. 12:68–73. 2000. View Article : Google Scholar : PubMed/NCBI
12.	Hoffman AR, Vu TH and Hu J: Mechanisms of genomic imprinting. Growth Horm IGF Res. 10:S18–S19. 2000. View Article : Google Scholar
13.	Jenuwein T and Allis CD: Translating the histone code. Science. 293:1074–1080. 2001. View Article : Google Scholar : PubMed/NCBI
14.	Kondo Y and Issa JP: Epigenetic changes in colorectal cancer. Cancer Metastasis Rev. 23:29–39. 2004. View Article : Google Scholar
15.	Sasaki H, Allen ND and Surani MA: DNA methylation and genomic imprinting in mammals. EXS. 64:469–486. 1993.PubMed/NCBI
16.	Efstratiadis A: Parental imprinting of autosomal mammalian genes. Curr Opin Genet Dev. 4:265–280. 1994. View Article : Google Scholar : PubMed/NCBI
17.	Reik W and Walter J: Genomic imprinting: parental influence on the genome. Nat Rev Genet. 2:21–32. 2001. View Article : Google Scholar : PubMed/NCBI
18.	Constancia M, Pickard B, Kelsey G and Reik W: Imprinting mechanisms. Genome Res. 8:881–900. 1998.
19.	Pollak M: Insulin-like growth factor physiology and neoplasia. Growth Horm IGF Res. 10:S6–S7. 2000. View Article : Google Scholar
20.	Pavelic K, Bukovic D and Pavelic J: The role of insulin-like growth factor 2 and its receptors in human tumors. Mol Med. 8:771–780. 2002.PubMed/NCBI
21.	Van Dijk MA, van Schaik FM, Bootsma HJ, Holthuizen P and Sussenbach JS: Initial characterization of the four promoters of the human insulin-like growth factor II gene. Mol Cell Endocrinol. 81:81–94. 1991.
22.	Kinouchi Y, Hiwatashi N, Higashioka S, Nagashima F, Chida M and Toyota T: Relaxation of imprinting of the insulin-like growth factor II gene in colorectal cancer. Cancer Lett. 107:105–108. 1996. View Article : Google Scholar : PubMed/NCBI
23.	Sussenbach JS, Steenbergh PH, Jansen E, et al: Structural and regulatory aspects of the human genes encoding IGF-I and -II. Adv Exp Med Biol. 293:1–14. 1991. View Article : Google Scholar : PubMed/NCBI
24.	Issa JP, Vertino PM, Boehm CD, Newsham IF and Baylin SB: Switch from monoallelic to biallelic human IGF2 promoter methylation during aging and carcinogenesis. Proc Natl Acad Sci USA. 93:11757–11762. 1996. View Article : Google Scholar : PubMed/NCBI
25.	DeChiara TM, Robertson EJ and Efstratiadis A: Parental imprinting of the mouse insulin-like growth factor II gene. Cell. 64:849–859. 1991. View Article : Google Scholar : PubMed/NCBI
26.	Giannoukakis N, Deal C, Paquette J, Goodyer CG and Polychronakos C: Parental genomic imprinting of the human IGF2 gene. Nat Genet. 4:98–101. 1993. View Article : Google Scholar : PubMed/NCBI
27.	Henry I, Bonaiti-Pellie C, Chehensse V, et al: Uniparental paternal disomy in a genetic cancer-predisposing syndrome. Nature. 351:665–667. 1991. View Article : Google Scholar : PubMed/NCBI
28.	Nicholls RD, Knoll JH, Butler MG, Karam S and Lalande M: Genetic imprinting suggested by maternal heterodisomy in nondeletion Prader-Willi syndrome. Nature. 342:281–285. 1989. View Article : Google Scholar : PubMed/NCBI
29.	Cerrato F, Sparago A, Verde G, et al: Different mechanisms cause imprinting defects at the IGF2/H19 locus in Beckwith-Wiedemann syndrome and Wilms’ tumour. Hum Mol Genet. 17:1427–1435. 2008.PubMed/NCBI
30.	Rainier S, Johnson LA, Dobry CJ, Ping AJ, Grundy PE and Feinberg AP: Relaxation of imprinted genes in human cancer. Nature. 362:747–749. 1993. View Article : Google Scholar : PubMed/NCBI
31.	Takano Y, Shiota G and Kawasaki H: Analysis of genomic imprinting of insulin-like growth factor 2 in colorectal cancer. Oncology. 59:210–216. 2000. View Article : Google Scholar : PubMed/NCBI
32.	Cui H, Horon IL, Ohlsson R, Hamilton SR and Feinberg AP: Loss of imprinting in normal tissue of colorectal cancer patients with microsatellite instability. Nat Med. 4:1276–1280. 1998. View Article : Google Scholar : PubMed/NCBI
33.	Kawakami K, Ruszkiewicz A, Bennett G, et al: DNA hypermethylation in the normal colonic mucosa of patients with colorectal cancer. Br J Cancer. 94:593–598. 2006. View Article : Google Scholar : PubMed/NCBI
34.	Cui H, Cruz-Correa M, Giardiello FM, et al: Loss of IGF2 imprinting: a potential marker of colorectal cancer risk. Science. 299:1753–1755. 2003. View Article : Google Scholar : PubMed/NCBI
35.	Ohta M, Sugimoto T, Seto M, et al: Genetic alterations in colorectal cancers with demethylation of insulin-like growth factor II. Hum Pathol. 39:1301–1308. 2008. View Article : Google Scholar : PubMed/NCBI
36.	Cruz-Correa M, Cui H, Giardiello FM, et al: Loss of imprinting of insulin growth factor II gene: a potential heritable biomarker for colon neoplasia predisposition. Gastroenterology. 126:964–970. 2004. View Article : Google Scholar : PubMed/NCBI
37.	Cruz-Correa M, Zhao R, Oviedo M, et al: Temporal stability and age-related prevalence of loss of imprinting of the insulin-like growth factor-2 gene. Epigenetics. 4:114–118. 2009. View Article : Google Scholar : PubMed/NCBI
38.	Bartolomei MS, Zemel S and Tilghman SM: Parental imprinting of the mouse H19 gene. Nature. 351:153–155. 1991. View Article : Google Scholar : PubMed/NCBI
39.	Brannan CI, Dees EC, Ingram RS and Tilghman SM: The product of the H19 gene may function as an RNA. Mol Cell Biol. 10:28–36. 1990.PubMed/NCBI
40.	Kuhn EJ and Geyer PK: Genomic insulators: connecting properties to mechanism. Curr Opin Cell Biol. 15:259–265. 2003. View Article : Google Scholar : PubMed/NCBI
41.	Moore T, Constancia M, Zubair M, et al: Multiple imprinted sense and antisense transcripts, differential methylation and tandem repeats in a putative imprinting control region upstream of mouse Igf2. Proc Natl Acad Sci USA. 94:12509–12514. 1997. View Article : Google Scholar
42.	Taniguchi T, Schofield AE, Scarlett JL, Morison IM, Sullivan MJ and Reeve AE: Altered specificity of IGF2 promoter imprinting during fetal development and onset of Wilms tumour. Oncogene. 11:751–756. 1995.PubMed/NCBI
43.	Sullivan MJ, Taniguchi T, Jhee A, Kerr N and Reeve AE: Relaxation of IGF2 imprinting in Wilms tumours associated with specific changes in IGF2 methylation. Oncogene. 18:7527–7534. 1999. View Article : Google Scholar : PubMed/NCBI
44.	Ulaner GA, Vu TH, Li T, et al: Loss of imprinting of IGF2 and H19 in osteosarcoma is accompanied by reciprocal methylation changes of a CTCF-binding site. Hum Mol Genet. 12:535–549. 2003. View Article : Google Scholar : PubMed/NCBI
45.	Byun HM, Wong HL, Birnstein EA, Wolff EM, Liang G and Yang AS: Examination of IGF2 and H19 loss of imprinting in bladder cancer. Cancer Res. 67:10753–10758. 2007. View Article : Google Scholar : PubMed/NCBI
46.	Murphy SK, Huang Z, Wen Y, et al: Frequent IGF2/H19 domain epigenetic alterations and elevated IGF2 expression in epithelial ovarian cancer. Mol Cancer Res. 4:283–292. 2006. View Article : Google Scholar : PubMed/NCBI
47.	Cui H, Onyango P, Brandenburg S, Wu Y, Hsieh CL and Feinberg AP: Loss of imprinting in colorectal cancer linked to hypomethylation of H19 and IGF2. Cancer Res. 62:6442–6446. 2002.PubMed/NCBI
48.	Monk D, Sanches R, Arnaud P, et al: Imprinting of IGF2 P0 transcript and novel alternatively spliced INS-IGF2 isoforms show differences between mouse and human. Hum Mol Genet. 15:1259–1269. 2006. View Article : Google Scholar : PubMed/NCBI
49.	Murrell A, Ito Y, Verde G, et al: Distinct methylation changes at the IGF2-H19 locus in congenital growth disorders and cancer. PLoS One. 3:e18492008. View Article : Google Scholar : PubMed/NCBI
50.	Ito Y, Koessler T, Ibrahim AE, et al: Somatically acquired hypomethylation of IGF2 in breast and colorectal cancer. Hum Mol Genet. 17:2633–2643. 2008. View Article : Google Scholar : PubMed/NCBI
51.	Pantoja C, de Los Rios L, Matheu A, Antequera F and Serrano M: Inactivation of imprinted genes induced by cellular stress and tumorigenesis. Cancer Res. 65:26–33. 2005.PubMed/NCBI
52.	De la Chapelle A: Microsatellite instability. N Engl J Med. 349:209–210. 2003.
53.	Ehrlich M: DNA methylation in cancer: too much, but also too little. Oncogene. 21:5400–5413. 2002. View Article : Google Scholar : PubMed/NCBI
54.	Alonso A, Moreno S, Valiente A, Artigas M, Perez-Juana A and Ramos Arroyo MA: Genetic mechanisms in the hereditary predisposition to colorectal cancer. An Sist Sanit Navar. 29:59–76. 2006.PubMed/NCBI
55.	Kikuchi T, Toyota M, Itoh F, et al: Inactivation of p57KIP2 by regional promoter hypermethylation and histone deacetylation in human tumors. Oncogene. 21:2741–2749. 2002. View Article : Google Scholar : PubMed/NCBI
56.	Perucho M: Tumors with microsatellite instability: many mutations, targets and paradoxes. Oncogene. 22:2223–2225. 2003. View Article : Google Scholar : PubMed/NCBI
57.	Kaz A, Kim YH, Dzieciatkowski S, et al: Evidence for the role of aberrant DNA methylation in the pathogenesis of Lynch syndrome adenomas. Int J Cancer. 120:1922–1929. 2007. View Article : Google Scholar : PubMed/NCBI
58.	Boland CR, Thibodeau SN, Hamilton SR, et al: A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 58:5248–5257. 1998.
59.	Perucho M: Correspondence ref: Boland CR, et al. A National Cancer Institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 58: 5248–5257, 1998. Cancer Res. 59:249–256. 1999.
60.	Hoang JM, Cottu PH, Thuille B, Salmon RJ, Thomas G and Hamelin R: BAT-26, an indicator of the replication error phenotype in colorectal cancers and cell lines. Cancer Res. 57:300–303. 1997.PubMed/NCBI
61.	Ribic CM, Sargent DJ, Moore MJ, et al: Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. 349:247–257. 2003. View Article : Google Scholar : PubMed/NCBI
62.	Lothe RA, Peltomaki P, Meling GI, et al: Genomic instability in colorectal cancer: relationship to clinicopathological variables and family history. Cancer Res. 53:5849–5852. 1993.PubMed/NCBI
63.	Nishihara S, Hayashida T, Mitsuya K, et al: Multipoint imprinting analysis in sporadic colorectal cancers with and without micro-satellite instability. Int J Oncol. 17:317–322. 2000.PubMed/NCBI
64.	Nakagawa H, Chadwick RB, Peltomaki P, Plass C, Nakamura Y and de La Chapelle A: Loss of imprinting of the insulin-like growth factor II gene occurs by biallelic methylation in a core region of H19-associated CTCF-binding sites in colorectal cancer. Proc Natl Acad Sci USA. 98:591–596. 2001. View Article : Google Scholar : PubMed/NCBI
65.	Sasaki J, Konishi F, Kawamura YJ, Kai T, Takata O and Tsukamoto T: Clinicopathological characteristics of colorectal cancers with loss of imprinting of insulin-like growth factor 2. Int J Cancer. 119:80–83. 2006. View Article : Google Scholar : PubMed/NCBI
66.	Sherr CJ and Roberts JM: CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 13:1501–1512. 1999. View Article : Google Scholar : PubMed/NCBI
67.	Lee MH, Reynisdottir I and Massague J: Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev. 9:639–649. 1995. View Article : Google Scholar : PubMed/NCBI
68.	Reid LH, Crider-Miller SJ, West A, Lee MH, Massague J and Weissman BE: Genomic organization of the human p57KIP2 gene and its analysis in the G401 Wilms’ tumor assay. Cancer Res. 56:1214–1218. 1996.PubMed/NCBI
69.	Orlow I, Iavarone A, Crider-Miller SJ, et al: Cyclin-dependent kinase inhibitor p57KIP2 in soft tissue sarcomas and Wilms’ tumors. Cancer Res. 56:1219–1221. 1996.
70.	Hatada I and Mukai T: Genomic imprinting of p57KIP2, a cyclin-dependent kinase inhibitor, in mouse. Nat Genet. 11:204–206. 1995. View Article : Google Scholar : PubMed/NCBI
71.	Hatada I, Inazawa J, Abe T, et al: Genomic imprinting of human p57KIP2 and its reduced expression in Wilms’ tumors. Hum Mol Genet. 5:783–788. 1996.
72.	Cost GJ, Thompson JS, Reichard BA, Lee JY and Feinberg AP: Lack of imprinting of three human cyclin-dependent kinase inhibitor genes. Cancer Res. 57:926–929. 1997.PubMed/NCBI
73.	Matsuoka S, Thompson JS, Edwards MC, et al: Imprinting of the gene encoding a human cyclin-dependent kinase inhibitor, p57KIP2, on chromosome 11p15. Proc Natl Acad Sci USA. 93:3026–3030. 1996. View Article : Google Scholar : PubMed/NCBI
74.	Thompson JS, Reese KJ, DeBaun MR, Perlman EJ and Feinberg AP: Reduced expression of the cyclin-dependent kinase inhibitor gene p57KIP2 in Wilms’ tumor. Cancer Res. 56:5723–5727. 1996.
75.	Ito Y, Takeda T, Sakon M, Tsujimoto M, Monden M and Matsuura N: Expression of p57/Kip2 protein in hepatocellular carcinoma. Oncology. 61:221–225. 2001. View Article : Google Scholar : PubMed/NCBI
76.	Shin JY, Kim HS, Lee KS, et al: Mutation and expression of the p27KIP1 and p57KIP2 genes in human gastric cancer. Exp Mol Med. 32:79–83. 2000. View Article : Google Scholar : PubMed/NCBI
77.	Lai S, Goepfert H, Gillenwater AM, Luna MA and El-Naggar AK: Loss of imprinting and genetic alterations of the cyclin-dependent kinase inhibitor p57KIP2 gene in head and neck squamous cell carcinoma. Clin Cancer Res. 6:3172–3176. 2000.PubMed/NCBI
78.	Noura S, Yamamoto H, Sekimoto M, et al: Expression of second class of KIP protein p57KIP2 in human colorectal carcinoma. Int J Oncol. 19:39–47. 2001.PubMed/NCBI
79.	Li JQ, Wu F, Usuki H, et al: Loss of p57KIP2 is associated with colorectal carcinogenesis. Int J Oncol. 23:1537–1543. 2003.PubMed/NCBI
80.	Ito Y, Yoshida H, Nakano K, et al: Expression of p57/Kip2 protein in normal and neoplastic thyroid tissues. Int J Mol Med. 9:373–376. 2002.PubMed/NCBI
81.	Sui L, Dong Y, Ohno M, Watanabe Y, Sugimoto K and Tokuda M: Expression of p57kip2 and its clinical relevance in epithelial ovarian tumors. Anticancer Res. 22:3191–3196. 2002.PubMed/NCBI
82.	Shin JY, Kim HS, Park J, Park JB and Lee JY: Mechanism for inactivation of the KIP family cyclin-dependent kinase inhibitor genes in gastric cancer cells. Cancer Res. 60:262–265. 2000.PubMed/NCBI
83.	Gazzoli I, Loda M, Garber J, Syngal S and Kolodner RD: A hereditary nonpolyposis colorectal carcinoma case associated with hypermethylation of the MLH1 gene in normal tissue and loss of heterozygosity of the unmethylated allele in the resulting micro-satellite instability-high tumor. Cancer Res. 62:3925–3928. 2002.
84.	Suter CM, Martin DI and Ward RL: Germline epimutation of MLH1 in individuals with multiple cancers. Nat Genet. 36:497–501. 2004. View Article : Google Scholar : PubMed/NCBI
85.	Hitchins M, Williams R, Cheong K, et al: MLH1 germline epimutations as a factor in hereditary nonpolyposis colorectal cancer. Gastroenterology. 129:1392–1399. 2005. View Article : Google Scholar : PubMed/NCBI
86.	Hitchins MP, Wong JJ, Suthers G, et al: Inheritance of a cancer-associated MLH1 germ-line epimutation. N Engl J Med. 356:697–705. 2007. View Article : Google Scholar : PubMed/NCBI
87.	Kolonel LN: Cancer patterns of four ethnic groups in Hawaii. J Natl Cancer Inst. 65:1127–1139. 1980.PubMed/NCBI
88.	Kmet J: The role of migrant population in studies of selected cancer sites: a review. J Chronic Dis. 23:305–324. 1970. View Article : Google Scholar : PubMed/NCBI
89.	Slattery ML, Potter JD, Samowitz W, Schaffer D and Leppert M: Methylenetetrahydrofolate reductase, diet and risk of colon cancer. Cancer Epidemiol Biomarkers Prev. 8:513–518. 1999.PubMed/NCBI
90.	Hubner RA and Houlston RS: Folate and colorectal cancer prevention. Br J Cancer. 100:233–239. 2009. View Article : Google Scholar : PubMed/NCBI
91.	Feinberg AP, Gehrke CW, Kuo KC and Ehrlich M: Reduced genomic 5-methylcytosine content in human colonic neoplasia. Cancer Res. 48:1159–1161. 1988.PubMed/NCBI
92.	Giovannucci E: Epidemiologic studies of folate and colorectal neoplasia: a review. J Nutr. 132:S2350–S2355. 2002.
93.	Chen J, Giovannucci E, Kelsey K, et al: A methylenetetrahydrofolate reductase polymorphism and the risk of colorectal cancer. Cancer Res. 56:4862–4864. 1996.PubMed/NCBI
94.	Frosst P, Blom HJ, Milos R, et al: A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 10:111–113. 1995. View Article : Google Scholar : PubMed/NCBI
95.	Ma J, Stampfer MJ, Giovannucci E, et al: Methylenetetrahydrofolate reductase polymorphism, dietary interactions and risk of colorectal cancer. Cancer Res. 57:1098–1102. 1997.PubMed/NCBI
96.	Chen J, Giovannucci E, Hankinson SE, et al: A prospective study of methylenetetrahydrofolate reductase and methionine synthase gene polymorphisms, and risk of colorectal adenoma. Carcinogenesis. 19:2129–2132. 1998. View Article : Google Scholar : PubMed/NCBI
97.	Pande M, Chen J, Amos CI, Lynch PM, Broaddus R and Frazier ML: Influence of methylenetetrahydrofolate reductase gene polymorphisms C677T and A1298C on age-associated risk for colorectal cancer in a caucasian lynch syndrome population. Cancer Epidemiol Biomarkers Prev. 16:1753–1759. 2007. View Article : Google Scholar : PubMed/NCBI
98.	Osian G, Procopciuc L and Vlad L: MTHFR polymorphisms as prognostic factors in sporadic colorectal cancer. J Gastrointestin Liver Dis. 16:251–256. 2007.PubMed/NCBI
99.	Shannon B, Gnanasampanthan S, Beilby J and Iacopetta B: A polymorphism in the methylenetetrahydrofolate reductase gene predisposes to colorectal cancers with microsatellite instability. Gut. 50:520–524. 2002. View Article : Google Scholar : PubMed/NCBI
100.	Hubner RA, Lubbe S, Chandler I and Houlston RS: MTHFR C677T has differential influence on risk of MSI and MSS colorectal cancer. Hum Mol Genet. 16:1072–1077. 2007. View Article : Google Scholar : PubMed/NCBI
101.	Oyama K, Kawakami K, Maeda K, Ishiguro K and Watanabe G: The association between methylenetetrahydrofolate reductase polymorphism and promoter methylation in proximal colon cancer. Anticancer Res. 24:649–654. 2004.
102.	Kawakami K, Ruszkiewicz A, Bennett G, Moore J, Watanabe G and Iacopetta B: The folate pool in colorectal cancers is associated with DNA hypermethylation and with a polymorphism in methylenetetrahydrofolate reductase. Clin Cancer Res. 9:5860–5865. 2003.PubMed/NCBI
103.	Clarizia AD, Bastos-Rodrigues L, Pena HB, et al: Relationship of the methylenetetrahydrofolate reductase C677T polymorphism with microsatellite instability and promoter hypermethylation in sporadic colorectal cancer. Genet Mol Res. 5:315–322. 2006.PubMed/NCBI
104.	Eaton AM, Sandler R, Carethers JM, Millikan RC, Galanko J and Keku TO: 5,10-Methylenetetrahydrofolate reductase 677 and 1298 polymorphisms, folate intake, and microsatellite instability in colon cancer. Cancer Epidemiol Biomarkers Prev. 14:2023–2029. 2005. View Article : Google Scholar : PubMed/NCBI
105.	Li YN, Gulati S, Baker PJ, Brody LC, Banerjee R and Kruger WD: Cloning, mapping and RNA analysis of the human methionine synthase gene. Hum Mol Genet. 5:1851–1858. 1996. View Article : Google Scholar : PubMed/NCBI
106.	Chen LH, Liu ML, Hwang HY, Chen LS, Korenberg J and Shane B: Human methionine synthase. cDNA cloning, gene localization and expression. J Biol Chem. 272:3628–3634. 1997. View Article : Google Scholar : PubMed/NCBI
107.	Ma J, Stampfer MJ, Christensen B, et al: A polymorphism of the methionine synthase gene: association with plasma folate, vitamin B12, homocyst(e)ine and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev. 8:825–829. 1999.PubMed/NCBI
108.	Paz MF, Avila S, Fraga MF, et al: Germ-line variants in methyl-group metabolism genes and susceptibility to DNA methylation in normal tissues and human primary tumors. Cancer Res. 62:4519–4524. 2002.PubMed/NCBI
109.	Matsuo K, Hamajima N, Hirai T, et al: Methionine synthase reductase gene A66G polymorphism is associated with risk of colorectal cancer. Asian Pac J Cancer Prev. 3:353–359. 2002.PubMed/NCBI
110.	Leclerc D, Wilson A, Dumas R, et al: Cloning and mapping of a cDNA for methionine synthase reductase, a flavoprotein defective in patients with homocystinuria. Proc Natl Acad Sci USA. 95:3059–3064. 1998. View Article : Google Scholar : PubMed/NCBI
111.	Olteanu H, Munson T and Banerjee R: Differences in the efficiency of reductive activation of methionine synthase and exogenous electron acceptors between the common polymorphic variants of human methionine synthase reductase. Biochemistry. 41:13378–13385. 2002. View Article : Google Scholar
112.	Ulrich CM, Curtin K, Potter JD, Bigler J, Caan B and Slattery ML: Polymorphisms in the reduced folate carrier, thymidylate synthase, or methionine synthase and risk of colon cancer. Cancer Epidemiol Biomarkers Prev. 14:2509–2516. 2005. View Article : Google Scholar : PubMed/NCBI